Newsletter · · Ashutosh Agarwal

UnitedHealth Beat and Raise Signals the Managed Care Turnaround Is Real - Managed Care Under Pressure - Week of July 18, 2026

Managed-care podcast intelligence for the week of July 11 to 18, 2026. UnitedHealth's Q2 beat-and-raise and a 320-basis-point drop in its medical-cost ratio reopened the insurer turnaround debate, alongside Elevance's star-ratings suit against CMS, a regional Medicare Advantage shakeout, OptumRx's PBM pricing overhaul, and Medicare's new $245 GLP-1 price anchor.

Managed Care Under Pressure

Week of July 18, 2026: UnitedHealth Beat and Raise Signals the Managed Care Turnaround Is Real

UnitedHealth's beat-and-raise says the turnaround is real.

After more than a month of a genuinely quiet podcast tape, the microphones finally turned back to managed care this week, and the trigger was the biggest one possible. UnitedHealth (UNH) reported second-quarter results on Wednesday, July 16, and it was the report the whole sector has been waiting on. It topped estimates, raised full-year guidance for the second time this year, and, most importantly, showed that the medical-cost problem that blew this company up in 2025 is actually starting to come under control. General-market shows piled in, a couple of real buy-side voices weighed in, and the star-ratings litigation story we led with last week took a concrete step forward when Elevance (ELV) sued the government. Below is the whole week, in depth.

TL;DR

  • UNH delivered a clean beat-and-raise for Q2'26. Revenue of $112B and EPS of $6.38 both beat; the medical cost ratio improved to 86.2% from 89.4% a year ago; and full-year 2026 adjusted EPS guidance went up to $19.50–$20.00 from "more than $18.25." The stock, already up ~27% for the year, jumped another ~7% on the print. The turnaround thesis just got its first hard data point.

  • The star-ratings lawsuits we flagged last week became real. Elevance (Anthem's parent) formally sued CMS over how it recalculated 2026 Medicare Advantage quality scores, saying it lost $115M in bonus payments. This is the exact "the whole industry has its teeth out" cascade we described a week ago, now with a named plaintiff and a dollar figure.

  • The regional Medicare Advantage shakeout is accelerating, and it favors the giants. Two regional carriers (Presbyterian in New Mexico, Providence in the Northwest) are pulling out of most MA plans for 2027, while Humana (HUM) guides to 25% MA membership growth and Clover Health grew members 51% year over year. Bigger and more diversified is winning the war of attrition.

What's new

1. UnitedHealth's Q2'26 beat-and-raise, the number the sector needed

This is the story of the week, and it is genuinely important, so let's do the numbers carefully.

On The Rundown (2026-07-16, general-market/pundit), the host laid out the headline figures: UNH reported revenue of $112 billion and earnings per share of $6.38, both above estimates. The bright spot was medical costs. UNH's medical cost ratio, the share of the premiums it collects that gets paid back out for patient care, improved to 86.2% in Q2'26, down from 89.4% in the same quarter last year. A lower number is better here, because it means the company keeps more of every premium dollar. That is a roughly 320-basis-point improvement year over year, and it is the single most important thing in the report. The host noted UNH "had a historic collapse last year after high medical costs crushed profits for the first time in over a decade," and that the stock was "already up 27% this year coming into today, and it's up another 7% this morning."

On Squawk on the Street (2026-07-16), CNBC health reporter Annika Kim Constantino, who has direct access to the company, added the color that matters. She called it "the biggest earnings beat since the second quarter of 2020," and confirmed the raise: "UNH now expects adjusted profit of $19.50 to $20 per share, up from a previous outlook of more than $18.25 per share", the second guidance raise of the year. Crucially, she relayed what UNH's CFO told her directly: medical costs are still higher than historical levels, an industry-wide issue as "more seniors use healthcare services and expensive drugs like GLP-1s", but the company is getting a better handle on them by raising premiums, adjusting plan benefits to better match rising costs, and cutting costs with AI. The CFO framed it as a multi-year turnaround that is only starting to pay off. On the AI point, Constantino was careful: the fear is that insurers use AI to deny care, but UNH says it is using AI to "streamline prior authorizations" and detect "fraud, waste, and abuse," and insists no claim will be approved or denied because of AI.

Why it matters: the entire managed-care bull case rests on whether the 2025 cost blowup was a one-time repricing miss or a permanent step-up in trend. A 320bp year-over-year improvement in the medical cost ratio, plus a second guidance raise, is the first real evidence for the "it was fixable" camp, and it sets the bar for CVS, HUM, ELV, CNC, and MOH when they report over the next few weeks.

2. A real buy-side voice: "Hemsley is a rock star… I think you should buy it"

We have complained for six weeks about the absence of any dedicated healthcare-investing podcast. We still don't have one, but this week the general-market shows delivered actual portfolio-manager commentary, which is the next best thing.

On Morning Call (2026-07-16), portfolio manager Stephanie Link, who owns the stock, made the bull case in plain terms. On CEO Stephen Hemsley, the longtime UnitedHealth veteran who returned as CEO last year after the company faltered, she said: "Hemsley, the CEO, is a rock star. And he's turning this company around. They repriced all of their membership when he got there… And they are also laser-focused on cost cuts and discipline." Her valuation point is the one to write down: "This stock is still value. It's like trading at 17 times earnings and about 18 times EBITDA. And this historically has traded in the 20s. So I like it. I think you should buy it. And I might even buy some more."

That framing, a repriced book, cost discipline, and a multiple still well below its own history, is the cleanest articulation of the long thesis we've heard on a podcast in months. It also quantifies the index effect: the show noted UNH shares up ~5% added roughly 140 points to the Dow on their own, given it is a price-weighted index.

Supporting detail came from Brew Markets (2026-07-16), which put a bottom-line figure on it: UNH reported net income of $5.5 billion, a 60% increase from a year ago, and described Hemsley's playbook, exiting unprofitable contracts, reshuffling leadership, and investing $1.5 billion in AI for efficiency. Schwab Network (2026-07-16) added the top-line guide, full-year 2026 revenue guidance of $439 billion, and reminded listeners how far the stock has traveled, from "that big dump from… $630 a share" down to "under $300 on the missteps that they had." Between them the shows also flagged the flip side of the AI story: as one Schwab host put it bluntly, the $1.5B AI push is "probably going to take some jobs out of UnitedHealthcare moving forward."

3. Elevance sues CMS, the star-ratings cascade gets a named plaintiff

Last week we led with the Medicare Advantage star-ratings litigation snowball. This week it moved from "the industry is suing" to a specific, quantified case.

Two podcasts covered it. On Health:Further (2026-07-11, healthcare-industry pundits), the hosts summarized it cleanly: Elevance sued CMS after a Medicare Advantage stars recalculation, saying it lost out on $115 million in bonus payments. They connected it directly to the Clover Health precedent, CMS recalculated Clover's scores using a different methodology than it applied to peers, and one host's read was pointed: "$115 million is real money… I think Elevance has a pretty good case."

The Medicare-agent show The Seven Figures Or Bust Podcast! (Ep. 249) (2026-07-13) walked through the mechanics in detail. Some plain-English background first: a "star rating" is CMS's 1-to-5 quality score for each Medicare Advantage plan, built from up to 43 measures (preventive care, chronic-condition management, member experience, complaints, customer service), and it is enormously consequential because higher stars mean bigger bonus payments. As the hosts explained, after Clover sued and won, "the CMS re-ran 2026 quality scores for Clover Health, dropping 20 measures that a judge ruled could not be factored in. Regulators then recalculated stars for other MA insurers last month, but cut out extra measures too, measures that Elevance performed well on." Elevance's complaint, filed in Georgia District Court, asks the court to force CMS to redo everyone's ratings using the same methodology it gave Clover. The hosts underscored the stakes: "Every half star could be worth tens of millions of dollars to the carriers," and for a national carrier like Elevance the swing "could be into the billions."

Why it matters: star-rating bonuses are a core piece of Medicare Advantage profitability, and the recalculation risk is now clearly a live, litigated, company-specific number rather than a background worry. It reads directly to UNH, HUM, and CVS's Aetna, all of whom sit in the same bonus pool.

4. The regional MA shakeout, and why scale is winning

The most useful strategic read of the week came from The Seven Figures Or Bust Podcast! (Ep. 251) (2026-07-17), hosted by Medicare insurance agents who see the plan-level carnage firsthand.

The news hook: Presbyterian Healthcare Services in Albuquerque, New Mexico, is discontinuing most of its Presbyterian Health Plan Medicare Advantage plans for 2027, citing financial losses. The MA plans "contributed to more than $59 million in losses for Presbyterian in 2025," and roughly 150 health-plan and administrative roles are being cut. Presbyterian is keeping only its dual-eligible special-needs plans (D-SNPs, plans for people who qualify for both Medicare and Medicaid). The hosts noted Fitch downgraded Presbyterian in February to AA- from AA with a negative outlook, citing "several years of weak operating performance, widened losses in fiscal 2025… persistently weak cash flow, rising medical costs and labor market challenges." They added that Providence Health Plan in the Northwest is also ending most of its insurance business for 2027, and may hand its MA members to a national carrier.

The contrast with the giants was the whole point. On their Q1 calls, Humana said it expects Medicare Advantage membership growth of about 25% this year, driven largely by retention of existing members, and Clover Health grew MA membership 51% year over year to 155,773 members, retaining over 95% of them. The hosts' takeaway: "bigger might be better… The bigger and more established… a carrier is, they're probably going to have an easier time weathering this storm," while regional carriers dependent on a single local market "might not be able to bounce back… They will win the war of attrition."

Why it matters: this is the on-the-ground evidence for the "consolidation into the nationals" thesis. Every regional exit is a book of members that eventually re-homes with a UNH, HUM, ELV, or CVS. It supports the large-cap MA franchises and is a structural tailwind that outlasts any single quarter's cost trend.

5. OptumRx moves first on PBM pricing: per-member-per-month, de-linked from drug prices

The most consequential operator development of the week for the PBM-reform debate came from Prescription for Better Access (2026-07-15), an interview with Kathryn "Kate" Carey, president of OptumRx, UnitedHealth's pharmacy-benefit arm.

Quick definition: a PBM (pharmacy benefit manager) is the middleman between drugmakers, insurers, and pharmacies that decides which drugs are covered and negotiates prices and rebates. The three big ones, OptumRx (UNH), Caremark (CVS), and Express Scripts (Cigna), have been the central target of "drug prices are too high and the middlemen are why" reform pressure.

Carey's announcement: OptumRx is rolling out a new pricing model that passes through every source of revenue for a flat per-member-per-month (PMPM) fee, de-linked from the price of drugs. In her words: "that gets a lot of headlines on the PBMs being incentivized by pricing of drugs… that consistent PMPM delinks us from any pricing changes." Rollout begins in 2027, and she forecasts 30% to 60% of clients adopting over the next couple of years. She also said OptumRx passes through 99% of rebates today, moving to 100% as contracts mature, will start reporting all its GPO (group purchasing organization) fees, and is "pushing to go against spread pricing."

Scale check, straight from her: OptumRx covers about 61 million lives, has roughly 5,000 clients, and processes 1.8 billion prescriptions a year. She said the change is financially neutral for both clients and OptumRx. Two other tidbits worth noting: OptumRx raised independent-pharmacy reimbursement last year, and she named the cause directly, "GLP-1s is a big, huge driver of the mix and why it's changed," squeezing pharmacies under the old pricing model. And on consumer tools, she said the specialty-pharmacy "Savings IQ" tool saved members over $870 million last year, while the "Price Edge" on/off-benefit tool has saved consumers over $270 million.

Why it matters: this is the largest PBM voluntarily changing the mechanic, price-linked economics, that regulators keep attacking. If it holds and clients adopt, it partly defuses the reform threat to UNH's most profitable engine; if it's mostly optics, the reform overhang stays. Either way, watch whether Caremark and Express Scripts feel forced to follow.

6. The GLP-1 cost anchor: Medicare is now paying $245 a month

Two podcasts put hard numbers on how the new Medicare GLP-1 "Bridge" program, which we noted went live July 1, is reshaping the cost picture.

On 4sight Health Roundup (2026-07-16, for healthcare executives), Dave Johnson (CEO of Foresight Health) gave the economics: Medicare is paying Lilly and Novo Nordisk $245 per month per prescription under the bridge program, with a $50 patient copay (that $50 does not count toward Part D deductibles or out-of-pocket maximums). He framed the price collapse starkly: Wegovy, which "wasn't that long ago" cost $1,350 a month, is now $245 for the government. The program runs 18 months, July 1, 2026 through December 2027, for Medicare beneficiaries with Part D whose plan doesn't already cover the drug. Julie Merchansen (partner at Transformation Capital) made the investor-relevant point: "CMS just did something no commercial payer has been willing to do. It set a price anchor… They negotiated a floor" of $245 net and $50 to the patient, a first among major payers, and a number every PBM and employer will now benchmark against. She also flagged the operational mess: pharmacies often can't tell at the point of sale whether a script is going through Bridge or Part D, and there's no formal appeals process.

On Thoughts on the Market (2026-07-13), Morgan Stanley's analyst put the access math in context: about 50% of US employers currently cover GLP-1s, expected to rise; the Medicare $50/month access "will broaden access to about an additional 18 million people starting this summer"; and cheaper oral versions are expanding the market, mostly to new users.

The counter-signal, from Consumerpedia (2026-07-16): on the commercial side, 11% of employers have dropped GLP-1 coverage and over 25% of large companies are adding restrictions like mandatory weigh-ins or health coaching.

Why it matters: GLP-1s are the swing variable in the specialty-drug cost line that Constantino's CFO source flagged as still-elevated. Lower per-script prices help the cost trend; broader Medicare and commercial access pushes volume the other way. The net effect on 2026–2027 medical and pharmacy costs is the number to keep modeling.

The debate

Bull: the cost trend has bottomed and 2026–2027 repricing is doing its job. The evidence this week is the strongest in a year. UNH's medical cost ratio fell 320bp year over year to 86.2%, it raised guidance twice, and a portfolio manager who owns it argued the stock trades at ~17x earnings versus a historical 20s multiple with a repriced membership book and hard cost discipline behind it (Morning Call). The regional shakeout hands members to the nationals (Seven Figures Ep. 251), OptumRx is defusing the PBM-reform threat on its own terms (Prescription for Better Access), and GLP-1 per-script prices are falling (4sight Health). If Q2 was the inflection, the group re-rates back toward normal multiples into 2027.

Bear: one clean quarter doesn't undo a structural reset, and the political/regulatory pipe is still leaking. Even the bull data comes with an asterisk: UNH's own CFO told CNBC that medical costs remain "higher than historical levels," and management is explicitly calling this a multi-year turnaround, not a one-quarter fix (Squawk on the Street). The star-ratings bonus pool, a core profit source, is now actively litigated, with Elevance quantifying a $115M hit (Health:Further). PBMs are extracting an estimated $41 of every $100 spent on generics (Relentless Health Value), keeping reform live. And on the exchange/Medicaid side, the funding backdrop is deteriorating: enhanced ACA subsidies expired, insurers already raised 2026 premiums ~26% expecting healthy members to drop out, and risk pools are getting sicker (Mostly Economics). The bear says: enjoy the beat, but the multi-year reset is intact.

The swing factor, as always, is whether Q2'26 was the trend inflection or a well-managed single quarter. This week tilted the balance toward the bulls, but only for UNH, and only for one quarter.

Stocks in play

UNH: the whole thesis, validated (for now). Bull: Q2'26 beat on revenue ($112B) and EPS ($6.38); medical cost ratio down to 86.2% from 89.4%; guidance raised twice to $19.50–$20.00 FY26 adjusted EPS; net income $5.5B (+60% YoY); ~17x earnings vs 20s historically; PM-endorsed turnaround under Hemsley (The Rundown, Squawk, Morning Call, Brew Markets). Bear: CFO admits costs still above historical; multi-year (not one-quarter) fix; top recipient of a now-litigated star-bonus pool; owns the OptumRx PBM that reform keeps targeting. Next catalyst / number to watch: whether the ~30% YTD move holds; H2'26 medical cost ratio versus the improved Q2 base; 2027 MA bid and benefit color; any DOJ MA-coding-probe movement (none this week).

CVS: reports next, into a friendlier tape. Bull: Caremark and the pharmacy footprint cushion Aetna; UNH's clean print sets a constructive backdrop for the whole group. Bear: Aetna carries the same MA cost and star-ratings exposure; Caremark sits squarely in the PBM-reform crosshairs. Next catalyst: Q2'26 Aetna medical benefit ratio versus guide; any read on whether Caremark follows OptumRx's PMPM move; strategic-review chatter (none this week).

HUM: the pure-play that's still growing members. Bull: guided to ~25% MA membership growth this year on retention, and stands to absorb members from exiting regionals (Seven Figures Ep. 251); cleanest MA leverage if funding is bottoming. Bear: maximum exposure to MA cost trend and the star-ratings/bonus-pool litigation. Next catalyst: Q2'26 medical cost ratio; whether membership growth carries the margin, or just the top line.

ELV: now a plaintiff. Bull: Carelon services arm plus 2027 repricing; a win against CMS restores $115M in bonus payments. Bear: it just quantified a $115M star-bonus hit and is in open litigation with its regulator; Medicaid attrition and exchange-subsidy risk on top (Health:Further, Seven Figures Ep. 249). Next catalyst: Q2'26 Medicaid and MA cost splits; any procedural movement in the CMS suit.

CNC: most exposed to the exchange squeeze. Bull: exchange and Medicaid scale. Bear: the ACA subsidy cliff hits exactly its book, enhanced subsidies expired, ~26% 2026 premium hikes, healthier members dropping, sicker risk pools (Mostly Economics). Next catalyst: Q2'26 health benefits ratio by segment; exchange membership and 2027 rate filings. (No CNC-specific coverage this week; read-through only.)

MOH: Medicaid in the crosshairs. Bull: disciplined Medicaid underwriting. Bear: most Medicaid-levered name into ~$1 trillion/decade of HR1 Medicaid cuts (phasing in after the midterms) (Mostly Economics). Next catalyst: Q2'26 medical cost ratio; state rate adequacy and RFP wins/losses. (Read-through only this week.)

CI: the PBM story, one step removed. Bull: Evernorth/Express Scripts growth; already exited Medicare Advantage, so no MA cost or star exposure. Bear: Express Scripts sits in the same PBM-reform and generic-spread frame that OptumRx is trying to get ahead of. Next catalyst: Q2'26 Evernorth growth; whether Express Scripts matches OptumRx's transparency/PMPM move.

Read-throughs

Medicaid and exchange insurers (CNC, MOH, ELV). The policy backdrop got materially worse this week even without a single insurer-specific headline. On Mostly Economics, Georgetown's Sabrina Corlette detailed the "perfect storm": enhanced ACA subsidies expired (marketplace enrollment had grown from 12M in 2021 to 24M in 2025); a middle-income "subsidy cliff" around $60k of income now means ~$8,000 annual premiums with zero help; insurers raised 2026 premiums ~26% anticipating healthy dropouts, with early 2027 filings again in double digits and risk pools already skewing sicker; and HR1's ~$1 trillion/decade of Medicaid cuts phase in after the midterms. Every one of those pressures flows straight through the exchange and Medicaid P&Ls of CNC, MOH, and ELV. Watch first-month-premium payment rates (early estimates point to a 20–30% drop) and 2027 rate filings.

PBMs and Optum-style services arms. The reform narrative is loud but the incumbents are maneuvering. OptumRx's PMPM/de-linking move (Prescription for Better Access) is a pre-emptive defense of UNH's most profitable engine. Against that, the critique keeps sharpening: Relentless Health Value argues PBMs extract $41 of every $100 spent on generics (drugs that cost ~47 cents to make), that 43% of top generics, 79% in the deductible phase, cost more through insurance than cash, and that generic uptake has slowed from one month to six because of formulary control. And a re-released Working Healthcare interview with former J&J executive Chuck Melendi repeated the framing that PBMs captured $850 billion in 2023 and that the five largest PBM/insurers generate ~$1.2 trillion in annual revenue. For UNH, CVS, and CI, this is the multi-year overhang that OptumRx is trying to get out in front of.

Hospitals and providers, the other side of utilization. The provider side is under real strain: Health:Further counted 10 healthcare bankruptcies at the 2026 midpoint (versus 15 in all of 2024 and 20 in 2025), and Presbyterian's own losses drove both an MA exit and a credit downgrade (Seven Figures Ep. 251). When a provider-owned health plan can't make MA math work and exits, its members become inbound growth for the national insurers, the read-through is negative for stressed regional providers and positive for large-cap MA franchises.

GLP-1 cost exposure. The Medicare Bridge set a $245 net / $50 patient price anchor that "every PBM and employer benchmarks against" (4sight Health), with access broadening to ~18M more people (Thoughts on the Market). Lower per-script prices help the cost line the UNH CFO flagged as still-elevated; broader access pushes volume up. On the commercial side employers are pulling back, 11% dropped coverage, 25%+ adding restrictions (Consumerpedia), a partial governor on volume. Net GLP-1 cost is still the biggest single swing in 2026–2027 managed-care models.

What changed vs last week

  • The tape woke up. After five to six weeks of a genuinely quiet podcast tape (and no dedicated healthcare-investing show), UNH's Q2'26 print pulled managed care back onto general-market, buy-side-adjacent, and trade podcasts. This is the busiest week of coverage in over a month.

  • Last week's "watch the Q2 print" catalyst resolved, to the bull side. A week ago we flagged that UNH/CVS had rallied ~30% YTD with Q2'26 not yet reported, and that Becker's analyst Jakob Emerson cautioned Q2 could look worse than the strong start to the year. UNH's actual Q2 result contradicted that caution: a beat, a 320bp year-over-year improvement in the medical cost ratio, and a second guidance raise. The H2'26 caution still stands, but Q2 itself was clean.

  • The star-ratings litigation we led with became a filed lawsuit. Last week's thread was "the entire industry is suing the government" after Clover's win. This week it has a named plaintiff (Elevance), a court (Georgia District Court), and a number ($115M).

  • PBM reform moved from re-releases to a real strategic action. Last week's PBM coverage was two re-released interviews. This week OptumRx's president announced a concrete, forward-dated pricing change (PMPM, de-linked from drug prices, rolling out 2027).

  • GLP-1 economics got quantified. Last week Centene's pharmacy chief confirmed the Bridge program launched July 1. This week we got the actual price anchor ($245 net to manufacturers, $50 to patients) and the access math (~18M more people).

  • Still absent (now six weeks running): a dedicated buy-side/sell-side healthcare-investing podcast; investor-desk quantification of V28 risk-adjustment phase-in and RADV audit exposure; any movement on the UNH DOJ MA-coding probe; and any M&A chatter (Optum carveout, CVS strategic review, Humana Medicaid sale). We still have no podcast coverage this week of the 2027 MA Rate Notice as a standalone topic.